Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Greenlight sees value in Chemours
by Michael McCoy
August 1, 2016
| A version of this story appeared in
Volume 94, Issue 31
The hedge fund Greenlight Capital disclosed in its second-quarter report to investors that it purchased a stake in the embattled chemical maker Chemours. Greenlight says it bought part of the stake in late 2015 when Chemours’s stock fell in reaction to low titanium dioxide prices. It bought the rest last month after the short seller Citron Research suggested Chemours is headed for bankruptcy in the wake of lawsuits related to perfluorooctanoic acid contamination. Greenlight says it believes Chemours’s debt and legal liabilities are manageable.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter